P011 - SectionFront Standard Page
Board of management
Steen Riisgaard
Chairman with extended operational responsibilities acting as CEO

Henrik Jacobi
Executive Vice President
Research & Development
Flemming Pedersen
CFO & Executive Vice President
Finance, IT, IR & Business Development
Søren Niegel
Executive Vice President
Commercial Operations

Helle Skov
Executive Vice President
Product Supply

Further information

About ALK 


ALK is a global research-driven pharmaceutical company that focuses on prevention, diagnosis and treatment of allergies. Since 1923 ALK has been working to improve the quality of life for allergy patients by developing drugs that target the cause of allergy.

ALK is the world leader in allergy immunotherapy - a unique treatment of the cause of allergies. The treatment induces a protective immune response that provides a sustained reduction of allergy symptoms and reduces the risk of developing asthma. ALK provides allergy immunotherapy products as injections, sublingual drops and sublingual tablets, which is the newest, best documented and most convenient treatment for patients. The portfolio of products also includes an adrenaline used to treat severe allergic reactions (anaphylactic shock).

ALK invests annually approx. 20% of revenue in research that aims to develop new, evidence-based allergy immunotherapy. Research and development pipeline includes sublingual allergy immunoterapy tablets against ragweed, house dust mite and tree pollen allergy. ALK has signed partnership agreements with Merck and Torii Pharmaceutical, concerning the development, registration and commercialisation of tablets in Northern America and Japan.

ALK has approx. 1,800 employees with subsidiaries, production facilities and distributors worldwide. The company headquarters is in Denmark and is listed on NASDAQ OMX Copenhagen  (OMX: ALK B). In
 2013 the turnover was more than DKK 2.2 billion (EURm 300).

Quick facts about ALK
ALK in Brief